FDA has recently revised Form 356h: Application to Market a New or Abbreviated New Drug or Biologic for Human Use and Form 1571: Investigational New Drug Application (IND) to align with FDA User Fee requirements as well as make other improvements to data quality and ease of use.
These forms are required to be submitted with NDAs, ANDAs, BLAs and INDs. FDA uses this information in the review process and companies should be aware of these updates and are required to use the most current version of these forms.
Companies need to use the most recent update to Forms 356h and 1571 in their submissions.
View referenced article
Author(s)
Related Insights
23 May 2025
Tariff & International Trade Resource
Oscar the Grouchy CCO
This Memorial Day marks 35 years since Jim Henson, creator of the Muppets, passed away. Among his many accomplishments, the Muppets were essential to the creation of the longest-running children’s television show, “Sesame Street,” which has been airing for over 55 years.
03 June 2025
Events
FO PRO: ALIGN: Connecting the Family and the Family Office
Foley partner, Nate Imfeld, and senior counsel, Nicholas Chamis, will be speaking at the upcoming ALIGN Conference, hosted by Family Business Magazine in Chicago, Illinois. They will be hosting the breakout session, Sports Teams, AI, Bitcoin and More.
04 June 2025
Events
Health Care Organizations: Reduce Cybersecurity Threats
Foley partner Jennifer Urban, chair of the firm’s Cybersecurity & Data Privacy Area of Focus, is speaking in Moss Adams’ upcoming webinar titled “Health Care Organizations: Reduce Cybersecurity Threats” on June 4.